Samuel Klempner, MD, Massachusetts General Hospital, Boston, MA, emphasizes the importance of testing for biomarkers HER2, PD-L1, and MSI/MMR in the clinic, to effectively treat patients with the appropriate therapeutics in advanced gastroesophageal cancer. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
